TY - JOUR T1 - The CURE trial: Using clopidogrel in acute coronary syndromes without ST-segment elevation JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 377 LP - 385 VL - 69 IS - 5 AU - Gregory P. Gerschutz AU - Deepak L. Bhatt Y1 - 2002/05/01 UR - http://www.ccjm.org/content/69/5/377.abstract N2 - In a large, randomized, placebo-controlled trial in centers that use a conservative approach to acute coronary syndromes, the antiplatelet drug clopidogrel (Plavix) decreased the rate of the combined end point of cardiovascular death, nonfatal myocardial infarction, or stroke by 20% in patients presenting with acute coronary syndromes without ST-segment elevation. The benefit was at the cost of an increase in bleeding, however. This strategy may need to be tailored in centers that use a more aggressive treatment strategy of early angiography and revascularization. ER -